Summary & Overview
HCPCS G9421: NSCLC Biopsy/Cytology Report Lacking Specific Histologic Classification
HCPCS Level II code G9421 denotes cases where pathology or cytology reports for primary non-small cell lung cancer (NSCLC) fail to document a specific histologic subtype, do not follow International Association for the Study of Lung Cancer (IASLC) guidance, or label the tumor as NSCLC-not otherwise specified without explanation. This designation matters nationally because accurate histologic classification guides targeted therapies, biomarker testing, and staging decisions that affect patient outcomes and downstream utilization. Major payers included in the discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare.
Readers will learn the clinical and reporting context for G9421, how classification gaps are captured in billing, and what aspects of reporting drive use of this code. The publication summarizes common service settings and the pathology service type involved, highlights implications for clinical documentation and quality measurement, and outlines the types of benchmarks and policy updates that typically relate to this code. Data limitations are noted where input fields were not provided. The content is intended for national audiences including billing staff, pathology departments, compliance officers, and payers interested in documentation quality and coding consistency for NSCLC histologic classification.
Billing Code Overview
HCPCS Level II code G9421 indicates that a primary non-small cell lung cancer (NSCLC) biopsy and cytology specimen report either does not document classification into a specific histologic type, documents a histologic type that does not follow IASLC guidance, or classifies the tumor as NSCLC-not otherwise specified (nsclc-nos) without providing an explanation. The service type is pathology/cytology specimen reporting and histologic classification. The typical site of service is hospital or outpatient pathology/laboratory settings where lung biopsy and cytology analyses are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old current or former smoker presents with a 3-cm spiculated right upper lobe pulmonary nodule found on diagnostic CT chest. The pulmonologist performs a CT-guided percutaneous core needle biopsy of the lung lesion with accompanying bronchoscopy-guided brushings and washings for cytology. Tissue and cytology specimens are submitted to surgical pathology. The pathology report documents non-small cell lung cancer (NSCLC) on morphologic grounds but does not classify the tumor into a specific histologic subtype (for example, adenocarcinoma or squamous cell carcinoma) nor provide correlation with IASLC guidance; the report may use the term NSCLC-NOS without explanation. The clinical workflow includes specimen accessioning, histologic processing, immunohistochemical stains (such as TTF-1, p40/p63), possible molecular reflex testing for EGFR/ALK/ROS1/PD-L1 as indicated, and communication of incomplete classification back to the treating team to guide further diagnostic steps or repeat biopsy if needed. Typical site of service is an outpatient imaging suite or ambulatory surgery center for CT-guided biopsy, or an endoscopy suite for bronchoscopy with cytology. Common patient presentation includes imaging findings suspicious for primary lung malignancy with need for tissue diagnosis to determine histologic type and molecular testing eligibility.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |